Аннотация
Введение. Существует единое мнение, что хроническое воспаление и его медиаторы, в частности IL-6, могут способствовать возникновению злокачественной опухоли и ее прогрессированию.
Цель — оценка концентрации IL-6 в периферической крови у онкологических пациентов в зависимости от стадии заболевания.
Материал и методы. Проведено исследование содержания IL-6 в плазме периферической крови иммуноферментным методом у 82 онкологических пациентов (колоректальный рак, рак лёгкого, рак почки) на разных стадиях заболевания до лечения. Контрольную группу составили 50 человек соответствующего возраста и пола, без онкопатологии и с отсутствием острых, хронических, аутоиммунных заболеваний.
Результаты. Отмечено статистически значимое увеличение концентрации IL-6 у онкологических пациентов с III-IV стадией по сравнению с показателями пациентов с I-II стадией заболевания и контрольной группой.
Выводы. Анализ данных литературы и собственного материала подтвердил необходимость исследования в деталях вовлечения IL-6 в прогрессию злокачественных заболеваний.
Annotation
Background. Currently, there is a consensus that chronic inflammation and its mediators, in particular interleukin-6 (IL-6), can contribute to the development of malignant tumors and their progression.
Aim. Evaluation of IL-6 concentration indicators in peripheral blood of cancer patients depending on the stage of the disease.
Material and methods. A study of the content of IL-6 in the peripheral blood plasma was conducted using ELISA in 82 cancer patients (colorectal cancer, lung cancer and kidney cancer) at different stages of the disease before treatment. The control group consisted of 50 people of the corresponding age and gender, without oncopathology and with the absence of acute, chronic and autoimmune diseases.
Results. A statistically significant increase in the concentration of IL-6 was noted in cancer patients with stage III-IV compared with the indicators of patients with stage I-II of the disease and the control group.
Conclusions. The analysis of literary data and our own material confirmed the need for a detailed study of the involvement of IL-6 in the progression of malignant diseases.
Key words: interleukin-6; cancer patients; stage of disease
Список литературы
ЛИТЕРАТУРА (пп. 1-12, 14-18 см. REFERENCES)
13. Дмитриева О.С., Шиловский И.П., Хаитов М.Р., Гривенников С.И. Интерлейкин 1 и Интерлейкин 6 как главные медиаторы воспаления при развитии рака. Биохимия. 2016; 81 (2): 166-78. DOI: 10.1134/S0006297916020024.
REFERENCES
1. Hirano T.K., Yasukawa K., Harada H., Taga T., Watanabe Y., Matsuda T, et al Complementary DNA for a moved human interleukin (BSF-2) that induce B lymphocytes to produce immunoglobulin. Nature. 1986; 324:73-6. DOI: 10.1038/324073a0.
2. Kishimoto T. The biology of interleukin-6. Blood. 1989; 74: 1-10. DOI:10.1182/BLOOD.V74.1.1.BLOODJOURNAL7411 Corpus ID: 16861486.
3. Li L., Yu R., Cai T., Chen Z., Lan M., Zou T. et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int. Immunopharmacol. 2020; 88:106939. DOI: 10.1016/j.intimp.2020.106939.
4. Huang B, Lang H, Li H. The role of IL-6/JAK2/STAT3 signaling pathway in cancer. Front. Oncol. 2022; 12:1023177. DOI: 10.3389/fonc.2022.1023177.
5. Xiao J., Gong W., Chen W., Yu D., Wang H., Zhang H., et al. IL-6 promotes epithelial-to-mesenchymal transition of human peritoneal mesenchymal cells, possibly via the JAK2/STAT3 signaling pathway. Am. J. Physiol. Renal. Physiol. 2017; 313(2): F310–f8. DOI: 10.1152/ajprenal.00428.2016.
6. Zhang X., Hu F., Li G., Li G., Yang X., Liu L. et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression via IL-6/JAK2/STAT3 signaling. Disorder of cell death. 2018; 9(2): 25. DOI: 10.1038/s41419-017-0176-3.
7. Raj V., Bhadauria A.S., Singh A.K., Kumar U., Rai A., Keshari A.K. et al. Novel 1,3,4-thiadiazoles inhibit colorectal cancer via blockade of IL-6/COX-2-mediated JAK2/STAT3 signaling as confirmed by data-driven mathematical modeling. Cytokine. 2019; 118:144-59. DOI: 10.1016/j.cyto.2018.03.026.
8. Fang X., Hong Y., Dai L., Qian Y., Zhu C., Wu B. et al. CRH promotes human colon cancer cell proliferation via IL-6/JAK2/STAT3 signaling pathway and VEGF-induced tumor angiogenesis. Mol. Carcinogene. 2017; 56(11): 2434-45. DOI: 10.1002/mc.22691
9. Sun C., Yang J., Cheng H.B., Shen W.X., Jiang Z.Q., Wu M.J. et.al. 2-Hydroxy-3-methylanthraquinone inhibits lung carcinoma cells via modulation of IL-6-induced JAK2/STAT3 pathway. Phytomed: Int. J. phytother phytopharmacol. 2019. 61:152848. DOI: 10.1016/j.phymed.2019.152848.
10. Nengroo M.A., Verma A., Datta D. Cytokine chemokine network in tumor microenvironment: Impact on CSC properties and therapeutic applications. Cytokine. 2022; 156:155916. DOI: 10.1016/j.cyto.2022.155916.
11. Arashi M., Mangani R., Heydarnejad Maleki A., Hamidi A., Rostami S., Safe Sh. et al. Recent advances in targeted therapy for non-small cell lung cancer; an updated review. Cancer Cell Int. 2023; 23(1):162. DOI: 10.1186/s12935-023-02990-y.
12. World Medical Association, Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013; 310 (20): 2191-4. DOI: 10.1001/jama.2013.281053.
13. Dmitrieva O.S., Shilovskiy I.P., Khaitov M.P. Grivennikov S.I. Interleukin-1 and interleukin-6 as main mediators of inflammation and cancer. Biochimia. 2016; 81 (2):166-78. DOI: 10.1134/S0006297916020024. (in Russian)
14. Grivennikov S.I. Inflamation and colorectal cancer. Semin.Immunopathol. 2013; 35: 229-44. DOI: 1017/s00281-012-0352-6.
15. Browning L., Patel M.R., Horvath E.B., Tawara K., Djorcik K.L. IL-6 and ovarian cancer: inflammatory cytokines in promotion and metastasis. Cancer Manag. Res. 2018; 10: 6685-93. DOI: 10.2147/CMAR.SI.79189.R.S179189. eCollection 2018.
16. Manore S.G., Doheny D., Wang G.L., Hui-Wen Lo. L-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Front. Oncol. 2022; 12, article 866014. DOI: 10.3389/fonc.2022.866014.
17. Rašková M, Lacina L, Kejík Z, Venhauerová A, Skaličková M., Kolář M. et al. The role of IL-6 in cancer cell invasiveness and metastasis-overview and therapeutic opportunities. Cells. 2022; 11 (22): 3698. DOI: 10.3390/cells11223698.
18. Eskandari F., Dürr M., Buddy K., Dober K., Reindl-Schwaighofer R., Weiser J. et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 2019; 20 (37): 3158-6. DOI: 10.1186/s13063-018-3158-6.